Literature DB >> 7523720

The nature of prostate cancer detected through prostate specific antigen based screening.

D S Smith1, W J Catalona.   

Abstract

Prostate specific antigen (PSA) based screening nearly doubles the detection rate of early prostate cancer. However, it is unknown whether the additional tumors detected are medically important. Traditional clinical and pathological features associated with medically important cancer include a palpable tumor, multifocal or diffuse involvement and moderately or poorly differentiated histology. In contrast, microfocal, well differentiated tumors are considered to be possibly medically unimportant. We sought to examine the clinical and pathological tumor stage and tumor grade in 1,169 consecutive men whose prostate cancer was detected during serial PSA based screening protocols involving 24,346 men screened at 6-month intervals. Of the patients 97% had clinically localized (clinical stage T1 or T2) tumors, of which 39% were not palpable (stage T1). Of the men whose cancer was detected through initial screening who underwent surgical staging 69% had pathologically organ confined (pathological stage whose cancer was detected through initial screening pT1 or pT2) disease compared to 74% whose cancer was detected through serial screening (after an initially negative screening). Impalpable, clinically focal, well differentiated minimal tumors were noted in 16% of the men. However, only 3% of the men who underwent surgical staging had impalpable, pathologically microfocal, well differentiated minimal tumors. We conclude that the majority of tumors detected through PSA based screening have the clinical and pathological features associated with medically important prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523720     DOI: 10.1016/s0022-5347(17)32372-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

Review 1.  The significance of quality of life in health care.

Authors:  Robert M Kaplan
Journal:  Qual Life Res       Date:  2003       Impact factor: 4.147

Review 2.  Artificial neural networks for predictive modeling in prostate cancer.

Authors:  Eduard J Gamito; E David Crawford
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

Review 3.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

Review 4.  Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits.

Authors:  K G Marshall
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

5.  Mass screening of prostate cancer in Changchun City of China.

Authors:  Xiaomeng Li; Itiro Tsuji; Masaaki Kuwahara; Haifeng Zhang; Hongliang Wang; Ling Zhang; Guoyi Ji; Xuejian Zhao
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer.

Authors:  C R Pound; P C Walsh; J I Epstein; D W Chan; A W Partin
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

7.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

8.  Efficacy of Repeated Transrectal Prostate Biopsy in Men Younger Than 50 Years With an Elevated Prostate-Specific Antigen Concentration (>3.0 ng/mL): Risks and Benefits Based on Biopsy Results and Follow-up Status.

Authors:  Ho Gyun Park; Oh Seok Ko; Young Gon Kim; Jong Kwan Park
Journal:  Korean J Urol       Date:  2014-04-10

9.  Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy.

Authors:  Y Furuya; S Ohta; N Sato; T Kotake; M Masai
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

10.  The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis.

Authors:  Masakazu Tsutsumi; Tomoaki Miyagawa; Takeshi Matsumura; Natsui Kawazoe; Satoru Ishikawa; Tatsuro Shimokama; Tsuyoshi Shiina; Naoto Miyanaga; Hideyuki Akaza
Journal:  Int J Clin Oncol       Date:  2007-08-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.